Montreal – November 28, 2022 – The U.S. Food and Drug Administration (FDA) approved the first gene therapy for hemophilia B on November 22. Etranacogene...
Updated charts for products in the pipeline have been uploaded on the CHS website. The CHS publishes four charts, one each for clotting factor concentrates, inhibitor...
by David Page, CHS National Director of Health Policy Given recent advances in therapies for inherited bleeding disorders, especially hemophilia A and B, I have...
CLICK HERE to access the CHS 2020 Annual Report and the complete Financial Statements.
Updated charts for products in the pipeline have been uploaded on the CHS website. The CHS publishes four charts, one each for clotting factor concentrates,...
